The 36-month beta value for ATNM is also noteworthy at 0.14. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ATNM is 30.08M, and at present, short sellers hold a 7.54% of that float. The average trading volume of ATNM on October 04, 2024 was 821.54K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATNM) stock’s latest price update
Actinium Pharmaceuticals Inc (AMEX: ATNM) has experienced a decline in its stock price by -6.32 compared to its previous closing price of 1.90. However, the company has seen a fall of -0.56% in its stock price over the last five trading days. accesswire.com reported 2024-10-03 that LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE American:ATNM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATNM’s Market Performance
Actinium Pharmaceuticals Inc (ATNM) has experienced a -0.56% fall in stock performance for the past week, with a -1.11% drop in the past month, and a -74.46% drop in the past quarter. The volatility ratio for the week is 6.58%, and the volatility levels for the past 30 days are at 6.83% for ATNM. The simple moving average for the past 20 days is -2.92% for ATNM’s stock, with a -70.77% simple moving average for the past 200 days.
Analysts’ Opinion of ATNM
Many brokerage firms have already submitted their reports for ATNM stocks, with B. Riley Securities repeating the rating for ATNM by listing it as a “Neutral.” The predicted price for ATNM in the upcoming period, according to B. Riley Securities is $2 based on the research report published on August 07, 2024 of the current year 2024.
Stephens, on the other hand, stated in their research note that they expect to see ATNM reach a price target of $25. The rating they have provided for ATNM stocks is “Overweight” according to the report published on May 14th, 2024.
HSBC Securities gave a rating of “Buy” to ATNM, setting the target price at $11.60 in the report published on September 06th of the previous year.
ATNM Trading at -36.27% from the 50-Day Moving Average
After a stumble in the market that brought ATNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.62% of loss for the given period.
Volatility was left at 6.83%, however, over the last 30 days, the volatility rate increased by 6.58%, as shares surge +3.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -77.00% lower at present.
During the last 5 trading sessions, ATNM fell by -0.56%, which changed the moving average for the period of 200-days by -63.30% in comparison to the 20-day moving average, which settled at $1.8365. In addition, Actinium Pharmaceuticals Inc saw -64.96% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ATNM
Current profitability levels for the company are sitting at:
- -576.65 for the present operating margin
- -8.93 for the gross margin
The net margin for Actinium Pharmaceuticals Inc stands at -526.21. The total capital return value is set at -0.58. Equity return is now at value -87.96, with -45.12 for asset returns.
Based on Actinium Pharmaceuticals Inc (ATNM), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -18.37. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -85.39.
Currently, EBITDA for the company is -51.13 million with net debt to EBITDA at 1.83. When we switch over and look at the enterprise to sales, we see a ratio of -354.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.95.
Conclusion
In summary, Actinium Pharmaceuticals Inc (ATNM) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
